Abstract
Trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV), compared with TAS-102 monotherapy, was associated with a statistically significant and clinically relevant improvement in progression-free survival (PFS) with tolerable toxicity in a randomized, open-label, phase 2 trial. However, the role of this combination in a real-world setting is unknown.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
